In vivo magnetic resonance imaging of cell tropsim, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model

Biomaterials

Volumn 32, Issue 12, 2011, Pages 3275-3284

  Chien, Li Ying ^a   Hsiao, Jong Kai ^b,c   Hsu, Szu Chun ^b   Yao, Ming ^b   Lu, Chen Wen ^b   Liu, Hon Man ^b   Chen, Yao Chang ^b   Yang, Chung Shi ^a   Huang, Dong Ming ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Brain; Mesenchymal stem cell; MRI; Nanoparticle; Transplantation

Indexed keywords

BONE MARROW-DERIVED MESENCHYMAL STEM CELLS; BRAIN TUMORS; CELL LABELING; CLINICAL APPLICATION; DELIVERY VEHICLE; HIGH RESOLUTION; HUMAN MESENCHYMAL STEM CELLS; HUMAN MESENCHYMAL STEM CELLS (HMSCS); IN-VITRO; IN-VIVO; INHIBITORY EFFECT; IRON OXIDE PARTICLES; MESENCHYMAL STEM CELL; MOUSE BRAIN; MRI; STEM CELL LABELING; THERAPEUTIC IMPACT; TRANSPLANTATION;

CELL CULTURE; IRON OXIDES; NANOPARTICLES; RESONANCE; SIGNALING; STEM CELLS; TUMORS;

MAGNETIC RESONANCE IMAGING;

CHEMOKINE RECEPTOR CXCR4; FERUCARBOTRAN; PROTAMINE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL LABELING; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; STAINING AND LABELING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 79951773437     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.042     Document Type: Article

References (43)

1. Walker A.E., Robins M., Weinfeld F.D. Epidemiology of brain tumors: the national survey of intracraninal neoplasms. Neurology 1985, 35:219-226.
2. Louis D.N., Holland E.C., Cairncross J.G. Glioma classification: a molecular reappraisal. Am J Pathol 2001, 159:779-786.
3. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
4. Grossman S.A., Batara J.F. Current management of glioblastoma multiforme. Semin Oncol 2004, 31:635-644.
5. Ehtesham M., Stevenson C.B., Thompson R.C. Stem cell therapies for malignant glioma. Neurosurg Focus 2005, 19:E5.
6. Aboody K.S., Brown A., Rainov N.G., Bower K.A., Liu S., Yang W., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000, 97:12846-12851.
7. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000, 6:447-450.
8. Ehtesham M., Yuan X., Kabos P., Chung N.H., Liu G., Akasaki Y., et al. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 2004, 6:287-293.
9. Lesniak M.S. Targeted therapy for malignant: neural stem cells. Expert Rev Neurother 2006, 6:1-3.
10. Staflin K., Honeth G., Kalliomäki S., Kjellman C., Edvardsen K., Lindvall M. Neural progenitor cell lines inhibit rat tumor growth in vivo. Cancer Res 2004, 64:5347-5354.
11. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
12. Sonabend A.M., Ulasov I.V., Tyler M.A., Rivera A.A., Mathis J.M., Lesniak M.S. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008, 26:831-841.
13. Friedenstein A.J., Chailakhyan R.K., Gerasimov U.V. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987, 20:263-272.
14. Bianco P., Riminucci M., Gronthos S., Robey P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001, 19:180-192.
15. Tocci A., Forte L. Mesenchymal stem cells: use and perspectives. Hematol J 2003, 4:92-96.
16. Vogel G. Embryonic stem cells. Stem cells not so stealthy after all. Science 2002, 297:175-177.
17. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004, 11:1155-1164.
18. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 230:1235-1247.
19. Qiao L., Xu Z., Zhao T., Zhao Z., Shi M., Zhao R.C., et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008, 18:500-507.
20. Mailänder V., Lorenz M.R., Holzapfel V., Musyanovych A., Fuchs K., Wiesneth M., et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol 2008, 10:138-146.
21. Huang D.M., Hsiao J.K., Chen Y.C., Chien L.Y., Yao M., Chen Y.K., et al. The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials 2009, 30:3645-3651.
22. Bull B.S., Huse W.M., Brauer F.S., Korpman R.A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975, 69:685-689.
23. Arbab A.S., Yocum G.T., Kalish H., Jordan E.K., Anderson S.A., Khakoo A.Y., et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004, 104:1217-1223.
24. Golovko D.M., Henning T., Bauer J.S., Settles M., Frenzel T., Mayerhofer A., et al. Accelerated stem cell labeling with ferucarbotran and protamine. Eur Radiol 2010, 20:640-648.
25. Huang D.M., Hung Y., Ko B.S., Hsu S.C., Chen W.H., Chien C.L., et al. Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J 2005, 19:2014-2016.
26. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
27. Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., Daldrup-Link H.E. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004, 14:1851-1858.
28. Hsiao J.K., Tai M.F., Chu H.H., Chen S.T., Li H., Lai D.M., et al. Magnetic nanoparticle labeling of mesenchymal stem cells without transfection agent: cellular behavior and capability of detection with clinical 1.5 T magnetic resonance at the single cell level. Magn Reson Med 2007, 59:717-724.
29. Bulte J.W.M., Kraitchman D.L., Mackay A.M., Pittenger M.F. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling of with ferumoxides. Blood 2004, 104:3410-3412.
30. Arbab A.S., Yocum G.T., Rad A.M., Khakoo A.Y., Fellowes V., Read E.J., et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005, 18:553-559.
31. Mani V., Adler E., Briley-Saebo K.C., Bystrup A., Fuster V., Keller G., et al. Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model myocardial infraction. Magn Reson Med 2008, 60:73-81.
32. Sadek H., Latif S., Collins R., Garry M.G., Garry D.J. Use of ferumoxides for stem cells labeling. Regen Med 2008, 3:807-816.
33. Zhang Z., Jiang Q., Jiang F., Ding G., Zhang R., Wang L., et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 2004, 23:281-287.
34. Brekke C., Williams S.C., Price J., Thorsen F., Modo M. Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model. Neuroimage 2007, 37:769-782.
35. Thu M.S., Najbauer J., Kendall S.E., Harutyunyan I., Sangalang N., Gutova M., et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS ONE 2009, 4:e7218.
36. Josephson L., Tung C.H., Moore A., Weisseleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999, 10:186-191.
37. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18:410-414.
38. Gupta A.K., Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 2005, 26:1565-1573.
39. Wilhelm C., Billotey C., Roger J., Pons J.A., Bacri J.C., Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24:1001-1011.
40. Walczak P., Kedziorek D.A., Gilad A.A., Lin S., Bulte J.W.M. Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med 2005, 54:769-774.
41. Hunter A.C. Molecular hurdles in polyfection design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 2006, 58:1523-1531.
42. Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A., Moghimi S.M. Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett 2005, 579:6191-6198.
43. Chen Y.C., Hsiao J.K., Liu H.M., Lai I.Y., Yao M., Hsu S.C., et al. The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. Toxicol Appl Pharmacol 2010, 245:272-279.